At a glance
ClinicalIndex Comparison RecordN/ACompleted· 289 enrolled
Drug / intervention
dexamethasone intravitreal implant 0.7 mgdrug
Likely dose
dexamethasone intravitreal implant 0.7 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Retrospective Study in Patients Receiving Two or More OZURDEX® Injections for Retinal Vein Occlusion (RVO)
In Brief
An observational study evaluating dexamethasone intravitreal implant 0.7 mg for Retinal Vein Occlusion and Macular Edema. Completed, enrolled 289 participants across 1 site.
Detailed Summary
This is a retrospective data collection study to evaluate the efficacy, safety, and re-injection interval of OZURDEX® in the treatment of macular edema due to RVO. Following informed consent, there were no patient study visits. All data was collected via chart review.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsRetinal Vein Occlusion, Macular Edema
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartJul 2011
First PostedAug 2011
Primary CompletionMar 2012
TodayJul 2026
First PostedAug 8, 2011
Enrollment StartJul 1, 2011
Primary CompletionMar 1, 2012
TodayJul 2, 2026
Enrollment to primary: 8 monthsPosted 14.9 years ago
Interventions
dexamethasone intravitreal implant 0.7 mgdrug
Dexamethasone intravitreal implant 0.7 mg was dosed previously according to general clinical practice.